Finally, we found IDH1/2 mutation-positive patients with MDS who were treated with decitibine had a significantly longer OS (P = 0.023) suggesting hypomethylating agents might be an effective treatment option for these patients. This evidence concerns the gene IDH1 and myelodysplastic syndrome.